RecallRadar

FDA Drug recall D-0077-2025

Cinacalcet Tablets, 30 mg, packaged in: a) 30-count HDPE bottle (NDC 65862-831-30)

On 2024-12-11 the FDA classified a Class II recall of Cinacalcet Tablets, 30 mg, packaged in: a) 30-count HDPE bottle (NDC 65862-831-30) by Aurobindo Pharma Usa, citing cGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0077-2025
ClassificationClass II
Statusongoing
Initiated2024-11-07
Published2024-12-11
Last updated2026-09-13 11:52 UTC
CompanyAurobindo Pharma Usa
DistributionUS

Product

Cinacalcet Tablets, 30 mg, packaged in: a) 30-count HDPE bottle (NDC 65862-831-30); b) 500-count HDPE bottle (NDC 65862-831-05), Rx Only, Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road, East Windsor, NJ 08520, Made in India.

Reason

cGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit

Identifiers

code_info
Lot #: a) CFSA23001A, CFSA23002A, CFSA23003A, Exp 03/31/2025; CFSA23004A, Exp 07/31/2025; CFSA23005A, Exp 10/31/2025;…Lot #: a) CFSA23001A, CFSA23002A, CFSA23003A, Exp 03/31/2025; CFSA23004A, Exp 07/31/2025; CFSA23005A, Exp 10/31/2025; b) P2300191, P2300192, P2300193, P2300194, Exp 12/31/2024

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0077-2025%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.